BioCentury
ARTICLE | Clinical News

OGX-427: Phase II start

April 15, 2013 7:00 AM UTC

By the end of the quarter, OncoGenex said that the Sarah Cannon Research Institute will begin the double-blind, placebo-controlled, U.S. Phase II Spruce trial to compare IV OGX-427 plus carboplatin an...